GO:0031763 galanin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031763 (galanin receptor binding) is a molecular_function term defined as binding to a galanin receptor.
• The term describes the ligand side of galanin receptor signaling, encompassing the neuropeptide galanin and the related peptide spexin acting at GalR1, GalR2, and GalR3.
• Galanin receptor binding is studied with radioligand binding, NanoBRET, and structural methods that resolve how ligands engage these G protein-coupled receptors.
• Binding sites are distributed in hypothalamus, spinal cord, and other regions, where they respond to injury and modulate pain and autonomic signaling.
• Dysregulated galanin receptor binding is linked to atrial fibrillation, pain processing, and neuroendocrine biology, making it a target for peptide-based therapeutics.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of galanin receptor binding in disease-relevant cells.
Description
GO:0031763, galanin receptor binding, is a Gene Ontology molecular_function term that captures the ability of a ligand to bind a galanin receptor. Galanin receptors are G protein-coupled receptors (GPCRs) that recognize the neuropeptide galanin and the related peptide spexin, and the binding event is the first committed step in their signaling. Because the term is defined from the ligand perspective, it is used to annotate proteins and peptides that physically engage GalR1, GalR2, or GalR3, rather than the receptors themselves. Researchers care about galanin receptor binding because it sits at the interface between peptide pharmacology and receptor biology. Ligand binding assays have long been used to map receptor subtypes and their pharmacophores, and modern live-cell assays such as HiBiT-based NanoBRET now allow real-time quantification of ligand engagement at GalR1. Structural studies have further revealed how galanin and spexin dock into these receptors and stabilize distinct signaling conformations. From a disease perspective, galanin receptor binding is relevant to cardiac electrophysiology, pain, and neuroendocrine regulation. For example, spexin acting on GalR2 reduces atrial fibrillation vulnerability, and galanin receptor binding sites in spinal cord change after injury. This article summarizes the definition, mechanism, key genes, disease links, and experimental methods for studying GO:0031763.
galanin receptor binding At A Glance
| GO ID | GO:0031763 |
|---|---|
| GO term | galanin receptor binding |
| Ontology | molecular_function |
| Synonym | galanin receptor ligand |
| Definition | Binding to a galanin receptor. |
| Major function | Ligand recognition at GalR1, GalR2, and GalR3, initiating galanin receptor signaling. |
| Representative ligands | Galanin and spexin, which bind galanin receptors with subtype-dependent pharmacology. |
| Experimental readouts | Radioligand binding, NanoBRET ligand binding, and structural determination of ligand-receptor complexes. |
| Tissue context | Hypothalamus, spinal cord, and other regions where galanin receptor binding sites have been mapped. |
What Is GO:0031763?
In plain terms, GO:0031763 describes the molecular function of binding to a galanin receptor. The QuickGO definition states that this term is used for gene products that bind to a galanin receptor, and the synonym galanin receptor ligand reflects this ligand-centric view. It is a molecular_function term, not a biological process or cellular component, and it is therefore used to annotate the ligand side of galanin receptor interactions rather than the receptor's downstream signaling.
Why Is galanin receptor binding Important in Cell Biology?
Galanin receptor binding is important because it is the molecular gatekeeper for a peptide signaling system that influences cardiac rhythm, pain processing, and neuroendocrine function. Because the term is defined as binding to a galanin receptor, it provides a precise annotation target for ligands and ligand-like proteins, enabling researchers to distinguish receptor-proximal binding events from downstream signaling. This distinction matters for drug discovery, where assays such as NanoBRET and radioligand binding are used to quantify ligand engagement and compare subtype selectivity.
• Defines the ligand side of galanin receptor biology, complementing receptor-centric annotations.
• Enables pharmacological profiling of GalR1, GalR2, and GalR3 subtype selectivity.
• Supports live-cell quantification of ligand binding using NanoBRET at GalR1.
• Provides a structural framework for understanding peptide recognition by galanin receptors.
• Links to atrial fibrillation through spexin-GalR2 binding and downstream electrophysiological effects.
• Relevant to pain and spinal cord plasticity, where galanin receptor binding sites respond to injury.
• Helps interpret hypothalamic neuroendocrine circuits mapped by galanin mRNA and receptor binding sites.
• Guides development of peptide-based therapeutics that target galanin receptor binding.
• Offers a molecular_function annotation for CRISPR-based perturbation studies of ligand-receptor interactions.
Molecular Mechanism of galanin receptor binding
Ligand recognition and receptor engagement
In simple terms: A peptide ligand docks onto a galanin receptor like a key fitting a lock.
Galanin receptor binding begins when a ligand such as galanin or spexin engages the extracellular surface of a galanin receptor. The term GO:0031763 annotates the ligand side of this event, meaning the gene product that binds to the receptor. Subtype-specific pharmacophores determine whether a ligand prefers GalR1, GalR2, or GalR3, and these differences have been mapped using binding assays. Structural studies of galanin receptor signaling have provided insight into how peptide ligands are recognized and how binding is coupled to receptor activation.
Subtype selectivity and pharmacophore determinants
In simple terms: Different galanin receptors have different pockets, so the same ligand can bind one subtype better than another.
Galanin receptor subtypes show distinct ligand binding profiles, and key pharmacophores for binding to GalR2 have been identified. Comparative studies of galanin receptor subtypes have helped define how ligand chemistry influences subtype preference. This selectivity is central to interpreting GO:0031763 annotations, because a ligand may bind one galanin receptor with high affinity and another with low affinity. Live-cell assays such as the HiBiT peptide-based NanoBRET ligand binding assay for GalR1 provide quantitative readouts of these interactions.
Binding-coupled signaling and functional consequences
In simple terms: Once the ligand is bound, the receptor switches on signaling inside the cell.
Binding to a galanin receptor is the first step in receptor activation, which then engages downstream G protein-dependent pathways. Structural insights into galanin receptor signaling have clarified how ligand binding stabilizes active receptor conformations. In the heart, spexin binding to GalR2 reduces atrial fibrillation vulnerability, demonstrating that the binding event has direct physiological consequences. Thus, GO:0031763 is mechanistically upstream of the signaling outputs that are typically measured in functional assays.
Regulation of ligand availability and binding sites
In simple terms: The amount of ligand and the number of receptor binding sites can go up or down depending on the tissue and conditions.
Galanin receptor binding sites are distributed in a region-specific manner, as shown by mapping studies in human and rat hypothalamus. In the spinal cord, galanin receptor binding sites respond differentially to neonatal capsaicin, dorsal rhizotomy, and peripheral axotomy, indicating that binding site availability is dynamically regulated. These observations suggest that GO:0031763-dependent interactions are modulated by both ligand expression and receptor availability. Such regulation is important when designing experiments that measure binding in disease or injury models.
Experimental measurement of galanin receptor binding
In simple terms: Scientists measure binding with labeled ligands or engineered reporter systems.
Classical radioligand binding has been used to characterize galanin receptor subtypes and their ligand preferences. More recently, a HiBiT peptide-based NanoBRET ligand binding assay was developed for GalR1 in live cells, enabling real-time binding measurements. Autoradiographic mapping has been used to localize galanin receptor binding sites in hypothalamus and spinal cord. Together, these methods provide complementary ways to study GO:0031763 in native and recombinant systems.
Key Genes Involved in GO:0031763 galanin receptor binding
The following genes and peptides are central to galanin receptor binding, either as ligands that bind galanin receptors or as receptors that define the binding target.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAL | Encodes galanin, a neuropeptide ligand that binds galanin receptors. | Used to study ligand-receptor binding and subtype pharmacology. |
| SPX | Encodes spexin, a peptide ligand that acts on GalR2. | Studied for cardiac effects via GalR2 binding. |
| GALR1 | Encodes galanin receptor 1, a binding target for galanin and related peptides. | Target of NanoBRET ligand binding assays in live cells. |
| GALR2 | Encodes galanin receptor 2, a binding target with distinct pharmacophores. | Studied for spexin binding and atrial fibrillation biology. |
| GALR3 | Encodes galanin receptor 3, a galanin receptor subtype. | Included in subtype selectivity studies. |
| GNAI1 | Encodes Gi alpha subunit, a downstream transducer of galanin receptor signaling. | Relevant to signaling readouts after ligand binding. |
| GNAQ | Encodes Gq alpha subunit, a downstream transducer in galanin receptor signaling. | Used to interpret signaling consequences of binding. |
| ARRB1 | Encodes beta-arrestin 1, involved in GPCR regulation after ligand binding. | Studied in the context of galanin receptor desensitization. |
| ARRB2 | Encodes beta-arrestin 2, involved in GPCR regulation after ligand binding. | Studied in the context of galanin receptor desensitization. |
| GALR1 (isoforms) | Splice or species variants of galanin receptor 1. | Relevant to binding assay interpretation. |
| GALR2 (pharmacophore residues) | Residues that determine ligand binding to GalR2. | Mutagenesis targets for binding studies. |
| GAL (hypothalamic neurons) | Galanin mRNA-containing cells in hypothalamus. | Used to map ligand sources relative to binding sites. |
| GALR (spinal cord) | Galanin receptor binding sites in adult rat spinal cord. | Studied after injury and capsaicin treatment. |
| SPX (cardiac context) | Spexin ligand acting on GalR2 in the heart. | Tested for effects on atrial fibrillation vulnerability. |
| GALR1 (live-cell assay) | Receptor target in NanoBRET binding assays. | Used for real-time ligand binding quantification. |
| GALR2 (structural context) | Receptor target in structural studies of galanin receptor signaling. | Used to understand ligand recognition. |
| GALR3 (subtype context) | Galanin receptor subtype in binding studies. | Used for comparative pharmacology. |
| GAL (peptide ligand) | Endogenous ligand for galanin receptors. | Reference ligand in binding assays. |
How Is galanin receptor binding Regulated?
Galanin receptor binding is regulated at multiple levels. Ligand availability depends on expression of galanin and spexin, while receptor availability depends on expression and trafficking of GalR1, GalR2, and GalR3. Binding site density changes in response to injury, as shown in spinal cord after neonatal capsaicin, dorsal rhizotomy, and peripheral axotomy. In the hypothalamus, the distribution of galanin mRNA-containing cells and galanin receptor binding sites suggests region-specific regulation of ligand-receptor interactions. At the receptor level, GPCR regulatory proteins such as beta-arrestins participate in post-binding regulation of galanin receptor signaling.
galanin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALR2 / SPX | Atrial fibrillation vulnerability | Cardiac cell models with GalR2 knockout or spexin overexpression |
| GALR (spinal cord) | Pain and sensory plasticity after injury | Rodent spinal cord injury and capsaicin models |
| GAL / GALR | Hypothalamic neuroendocrine regulation | Hypothalamic cell models and mapping studies |
| GALR1 | Ligand binding pharmacology | Live-cell NanoBRET assays with GalR1 |
| GALR2 | Subtype-selective ligand binding | Mutagenesis of GalR2 pharmacophore residues |
Atrial fibrillation and cardiac electrophysiology
Spexin binding to GalR2 reduces atrial fibrillation vulnerability, linking galanin receptor binding to cardiac rhythm control. This finding positions GO:0031763 as a mechanistically relevant annotation for studies of peptide-based antiarrhythmic strategies. Experimental models that manipulate spexin-GalR2 binding can test whether the binding event is causal for the observed electrophysiological effects.
Pain and spinal cord plasticity
Galanin receptor binding sites in adult rat spinal cord respond differentially to neonatal capsaicin, dorsal rhizotomy, and peripheral axotomy, indicating a role in sensory plasticity. These observations connect GO:0031763 to pain processing and injury responses. Researchers can use spinal cord injury models to examine how changes in binding site density relate to sensory outcomes.
Neuroendocrine and hypothalamic function
Mapping studies have localized galanin mRNA-containing cells and galanin receptor binding sites in human and rat hypothalamus, supporting a role for galanin receptor binding in neuroendocrine circuits. This anatomical context is important for interpreting GO:0031763 in the brain. Hypothalamic models can be used to study how ligand and receptor distributions shape binding events.
From galanin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GalR2 alter spexin-dependent cardiac effects? | GALR2 knockout in cardiac cell models |
| Does a specific GalR2 residue control ligand binding? | Point mutation of GalR2 pharmacophore residues |
| Can a tagged GalR1 report ligand binding in live cells? | Knock-in of HiBiT-tagged GalR1 |
| Does overexpression of spexin change binding-dependent phenotypes? | Spexin overexpression in cardiac cells |
| How do galanin receptor binding sites change after injury? | Rodent spinal cord injury models |
| Where are galanin receptor binding sites distributed in brain? | Hypothalamic mapping studies |
How to Study the galanin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Ligand affinity and receptor density | Subtype pharmacology and pharmacophore analysis |
| NanoBRET ligand binding | Real-time ligand binding in live cells | GalR1 ligand screening and kinetics |
| Autoradiographic mapping | Spatial distribution of binding sites | Hypothalamus and spinal cord mapping |
| Structural biology | Ligand-receptor complex conformation | Understanding peptide recognition and signaling |
| Mutagenesis | Role of specific residues in binding | GalR2 pharmacophore dissection |
| Functional signaling assays | Downstream signaling after binding | Linking binding to G protein pathways |
| Injury models | Changes in binding site density | Spinal cord plasticity studies |
Radioligand binding assays
Radioligand binding is a classical method for measuring galanin receptor binding and has been used to characterize receptor subtypes and pharmacophores. It provides quantitative affinity estimates and can be applied to membranes from native tissues or recombinant cells. Autoradiographic mapping extends this approach to localize binding sites in hypothalamus and spinal cord.
NanoBRET ligand binding in live cells
The HiBiT peptide-based NanoBRET ligand binding assay for GalR1 enables real-time measurement of ligand binding in live cells. This method is useful for studying binding kinetics and for comparing ligands in a cellular context. It complements endpoint radioligand assays by providing dynamic readouts.
Structural biology of ligand-receptor complexes
Structural insights into galanin receptor signaling have revealed how peptide ligands engage these receptors and stabilize active conformations. Such structures help explain subtype selectivity and guide mutagenesis of binding determinants. They also provide a framework for interpreting GO:0031763 annotations at the molecular level.
Expression and localization studies
Mapping galanin mRNA-containing cells and galanin receptor binding sites in hypothalamus provides spatial context for ligand-receptor interactions. In spinal cord, binding site changes after injury can be assessed with autoradiography and related methods. These approaches connect GO:0031763 to tissue-level physiology.
How CRISPR Can Be Used to Study GO:0031763 galanin receptor binding
Knockout
CRISPR knockout of galanin receptor genes such as GALR2 can test whether ligand binding is required for downstream phenotypes, including cardiac effects of spexin. Knockout of ligand genes such as SPX can similarly remove the binding event and reveal its contribution. These models are useful for causal inference in galanin receptor binding research.
Point Mutation
Point mutations in galanin receptor residues that form the ligand binding pocket can dissect pharmacophore contributions, as suggested by studies of GalR2 binding determinants. Such mutations allow researchers to test whether a specific interaction is required for binding. They are also useful for validating structural models of ligand recognition.
Knock-in
Knock-in of tagged receptors, such as HiBiT-tagged GalR1, enables live-cell NanoBRET ligand binding assays in a native-like context. This approach preserves endogenous regulation while providing a sensitive binding readout. Knock-in models can also be used to introduce disease-associated or pharmacologically relevant variants.
Overexpression
Overexpression of ligands such as spexin can increase galanin receptor binding and amplify downstream effects, as shown in studies of atrial fibrillation vulnerability. Overexpression of receptors can increase binding capacity for pharmacological assays. These models are useful for gain-of-function studies of GO:0031763.
How EDITGENE Supports galanin receptor binding Research
Researchers studying galanin receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services that allow precise perturbation of galanin receptor binding components in relevant cellular contexts.
Contact EDITGENE today to design your custom CRISPR model for galanin receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GAL Knockout HEK293T Cell Line | EDJ-KQ97 | Human | 51083 | Details Get a Quote |
| GAL Knockout HEK293 Cell Line | EDJ-KQ2048 | Human | 51083 | Details Get a Quote |
| GAL Knockout HCT 116 Cell Line | EDJ-KQ17932 | Human | 51083 | Details Get a Quote |
| GAL Knockout A-549 Cell Line | EDJ-KQ23469 | Human | 51083 | Details Get a Quote |
| GAL Knockout HeLa Cell Line | EDJ-KQ23471 | Human | 51083 | Details Get a Quote |
Displaying Records 1 To 5 Of 5 Records
Frequently Asked Questions About galanin receptor binding
What is GO:0031763?
GO:0031763 is the Gene Ontology molecular_function term galanin receptor binding, defined as binding to a galanin receptor.
What does galanin receptor binding mean?
It describes the ability of a ligand, such as galanin or spexin, to physically bind a galanin receptor.
What genes are involved in galanin receptor binding?
Key genes include GAL, SPX, GALR1, GALR2, and GALR3, which encode ligands and receptors.
Which receptors bind galanin?
Galanin binds galanin receptors GalR1, GalR2, and GalR3, which are GPCRs with subtype-specific pharmacology.
How is galanin receptor binding measured?
It can be measured by radioligand binding, NanoBRET ligand binding, and autoradiographic mapping.
What is the role of galanin receptor binding in disease?
It is linked to atrial fibrillation through spexin-GalR2 binding and to pain-related spinal cord plasticity.
What is the synonym for GO:0031763?
The synonym is galanin receptor ligand.
Is galanin receptor binding a molecular function?
Yes, GO:0031763 is classified as a molecular_function term.
How can CRISPR be used to study galanin receptor binding?
CRISPR knockout, point mutation, knock-in, and overexpression can perturb ligands or receptors to test binding-dependent phenotypes.
Where are galanin receptor binding sites found?
They have been mapped in human and rat hypothalamus and in adult rat spinal cord.
Conclusion
GO:0031763, galanin receptor binding, is a precise molecular_function annotation for the ligand side of galanin receptor interactions. It connects peptide ligands such as galanin and spexin to GalR1, GalR2, and GalR3, and it is studied with radioligand binding, NanoBRET, structural biology, and mapping approaches. Disease links include atrial fibrillation, pain-related spinal cord plasticity, and hypothalamic neuroendocrine regulation. For researchers, the term provides a framework for causal experiments using CRISPR knockout, point mutation, knock-in, and overexpression models. EDITGENE supports these workflows with cell model generation, screening, and bioinformatics services tailored to galanin receptor binding research.
References
- 1. Li D et al.. 2024. Spexin Diminishes Atrial Fibrillation Vulnerability by Acting on Galanin Receptor 2.. Circulation 150(2):111-127 PMID: 38726666
- 2. Florén A et al.. 2000. Galanin receptor subtypes and ligand binding.. Neuropeptides 34(6):331-7 PMID: 11162289
- 3. Zhu H et al.. 2025. Development of a HiBiT Peptide-Based NanoBRET Ligand Binding Assay for Galanin Receptor 1 in Live Cells.. ACS Chem Biol 20(7):1594-1608 PMID: 40616201
- 4. Jiang W et al.. 2022. Structural insights into galanin receptor signaling.. Proc Natl Acad Sci U S A 119(21):e2121465119 PMID: 35594396
- 5. Lundström L et al.. 2005. Important pharmacophores for binding to galanin receptor 2.. Neuropeptides 39(3):169-71 PMID: 15944008
- 6. Wang S et al.. 1998. Galanin receptor subtypes.. Drug News Perspect 11(8):458-68 PMID: 15616674
- 7. Bonnefond C et al.. 1990. Distribution of Galanin mRNA Containing Cells and Galanin Receptor Binding Sites in Human and Rat Hypothalamus.. Eur J Neurosci 2(7):629-637 PMID: 12106297
- 8. Kar S et al.. 1994. Galanin receptor binding sites in adult rat spinal cord respond differentially to neonatal capsaicin, dorsal rhizotomy and peripheral axotomy.. Eur J Neurosci 6(12):1917-21 PMID: 7704302
